The first patient has been dosed with an orally available small molecule cancer immunotherapy drug, Sosei Group Corporation and Cancer Research UK have announced.
The Swiss company Idorsia has sold its operating businesses Idorsia Pharmaceuticals Japan Ltd and Idorsia Pharmaceuticals Korea Co., Ltd to the Japanese firm Sosei Heptares for CHF 400 million ($466 million).